NeuroSense Therapeutics Ltd.
Business
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases, including ALS, Alzheimer’s disease and Parkinson’s disease. Its main product candidate is PrimeC, an extended‑release oral fixed‑dose combination of ciprofloxacin and celecoxib, and it also advances preclinical and clinical programs such as StabiliC and an AD Phase 2 study. The company’s operations center on research and development, clinical trials, regulatory engagement and external manufacturing collaborations. It conducts multinational clinical trials and seeks regulatory pathways and commercial partnerships across Israel, Europe, Canada and the United States.
Summary from filing dated 2025-04-07
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-11.13M |
| Total assets | $1.03M |
| Total liabilities | $2.59M |
| Stockholders' equity | $-1.56M |
| Operating cash flow | $-7.67M |